Abstract Library

#4386 Streptozotocin- and temozolomide-based chemotherapy treatment in neuroendocrine neoplasms – Efficacy in patients treated outside clinical trials

Introduction: Chemotherapy treatment based on alkylating agents is useful in pancreatic and grade 3 neuroendocrine neoplasms (NENs). However, no current real-life data is available comparing streptozotocin (STZ) and temozolomide (TEM) combinations.

Conference:

Presenting Author: García-Álvarez A

Authors: García Alvarez A, Martínez-Badal S, García-Burillo A, Simó Perdigo M, Merino Casabiel X,

Keywords: Streptozotocin, temozolomide, neuroendocrine neoplasm,

#3838 Subgroup analysis of ORR and PFS of the SEQTOR study (GETNE 1206) – Everolimus followed by Streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs

Introduction: Previous global results of ORR and PFS1 have been presented. The best treatment (Tx) sequence between STZ-5FU and everolimus (EVE) in patients (pts) with advanced and progressive panNETs is not yet well established.

Conference:

Presenting Author: Salazar R

Authors: Capdevila J, Tafuto S, Krogh M, Teulé A, Garcia-Carbonero R,

Keywords: panNET, everolimus, STZ-5FU,

#3553 Gamma-glutamyltransferase as an indicator of hepatic tumor burden in neuroendocrine tumors

Introduction: In patients with neuroendocrine tumors (NETs) and liver metastasis, elevation of gamma-glutamyltransferase (GGT) is considered to be a sign of hepatic progression. However, there are no data supporting this assumption.

Conference:

Presenting Author: Schmidt B

Authors: Schmidt B, Leiderer M, Amin T, Viol F, Adam G,

Keywords: gamma glutamyltransferase, hepatic tumor burden, neuroendocrine tumor, liver metastasis, biomarker,

#3550 Randomized open label phase III study comparing the efficacy and safety of Everolimus followed by chemotherapy with Streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206)

Introduction: STZ-5FU and everolimus are frontline options for systemic treatment in patients with advanced and progressive pancreatic neuroendocrine tumors (panNETs). Switch between both upon progression is a common strategy, but the best sequence is not yet well established.

Conference:

Presenting Author: Salazar R

Authors: Capdevila J, Tafuto S, Vestermark L, Teulé A, Garcia-Carbonero R,

Keywords: pNET, everolimus, streptozotocin, 5FU, randomized trial,

#3403 Trends in chemotherapy use in neuroendocrine neoplasms: One step beyond guidelines

Introduction: The therapeutic landscape of neuroendocrine neoplasms (NENs) is constantly evolving. Current guidelines reflect the complexity of treatment sequences and mainly incorporate evidence from phase 3 clinical trials. Chemotherapy (CT) is a valuable option for patients with lung, pancreatic, and high-grade NENs, but proper phase 3 randomized studies are an unmet need. Nevertheless, several phase 2 studies with CT have been presented and published in the last year, with impact in both clinical practice and guidelines.

Conference:

Presenting Author:

Authors: Hernando J, Garcia-Diaz H, Bellas Fernandez L, Garcia Alvarez A, Roca M,

Keywords: Chemotherapy, CAPTEM, GUIDELINES,